top of page

Publication (2019)

Kim SB, Do IG, Tsang J, Kim TY, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng TY, Park S, Oh HS, Chiu J, Sohn J, Lee M, Choi YJ, Lee EM, Park KH, Nathaniel C, Ro
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.

J.Cancer Res Treat. 2019 Oct;51(4):1527-1539. doi: 10.4143/crt.2018.598. Epub 2019 Jun 4.PMID: 31163957

[Citation: 1 ] [IF: 3.76 (JCR 2019)] 

Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A.

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

Future Oncol. 2019 Jul;15(21):2489-2501. doi: 10.2217/fon-2019-0143. Epub 2019 May 29.PMID: 31140297 Clinical Trial.

[Citation: 5 ] [IF: 2.66 (JCR 2019)]

Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS; Asian Breast Cancer Cooperative Group
Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.

Breast Cancer Res Treat. 2019 Oct;177(3):549-559. doi: 10.1007/s10549-019-05318-5. Epub 2019 Jul 4.PMID: 31270763 Review.

[Citation: 15 ] [IF: 3.83 (JCR 2019)]

Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS; Asian Breast Cancer Cooperative Group.
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population.

J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306. doi: 10.1093/jnci/djz090.PMID: 31093668 

[Citation: 31 ] [IF: 13.76 (JCR 2011)]

El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
Oncologist 2019; 24(6):747-e218.

[Citation: 30 ] [IF: 5.03 (JCR 2019)]

Chiu JW, Leung R, Tang V, Cheuk WY, Lo J, Kwok GW, Wong H, Suen D, Cheung P, Wong TT, Yau T, Kwong A.
Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.
Postgrad Med J 2019; 95(1121):155-161.

[Citation: 1 ] [IF: 1.91 (JCR 2019)]

Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H,erson J, Cruz CD, Kudo M.
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
J Hepatol 2019; 71(3):543-552.

[Citation: 81 ] [IF: 20.58 (JCR 2019)]

Ng L, Kwan V, Chow A, Yau TC, Poon RT, Pang R, Law WL.
Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients.
BMC Cancer 2019; 19(1):713.

[Citation: 4 ] [IF: 3.15 (JCR 2019)]

Cheung TT, Chok KS, Chan AC, Tsang SH, Dai WC, Yau TC, Kwong A, Lo CM.
Survival analysis of breast cancer liver metastasis treated by hepatectomy: A propensity score analysis for Chinese women in Hong Kong.
Hepatobiliary Pancreat Dis Int 2019; 18(5):452-457.

[Citation: 3 ] [IF: 2.43 (JCR 2019)]

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Strans.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Cancer Discov 2019 Dec;9(12):1696-1707.

[Citation: 55 ] [IF: 29.50 (JCR 2019)]

Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, Gu Y, Sun Y, Tiedt R, Hao L, Song W, Tanwandee T.
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma 
Therapeutic Advances in Medical Oncology. 2019 Dec 11;11

[Citation: 19 ] [IF: 6.85 (JCR 2019)]

bottom of page